PNC-27 2mg — Vial Spec, Reconstitution Math & COA

Overview of PNC-27 2mg Lyophilized Format & Lab Applications

A 2mg vial of PNC-27 contains precisely 2,000 micrograms of pure lyophilized peptide, formulated specifically for controlled laboratory research environments. Research teams evaluating membrane disruption dynamics, receptor binding kinetics, or transformed cell line viability frequently select the 2mg unit size. This mass provides sufficient material for multiple microplate replicate series while limiting the exposure of reconstituted aliquots to degradation from extended storage.

PNC-27 consists of an HDM-2-binding domain derived from the p53 tumor suppressor protein (residues 12–26) attached to a cell-penetrating leader sequence derived from penetratin. In preclinical settings, this design allows investigators to isolate the physical mechanism of cell membrane lysis from classical intracellular gene transcription pathways. To review the complete range of available peptide mass options or source dedicated master stock, researchers can examine the core catalog at /all-peptides or inspect the primary product specification page at /product/pnc-27.

Molecular Structure and Target Binding Dynamics

The primary primary sequence of PNC-27 couples the HDM-2-binding alpha-helix of p53 to the membrane-integrating motif of penetratin. Preclinical studies suggest that the primary target for PNC-27 is HDM-2 (human double minute 2 protein) expressed specifically on the outer cell membrane of cancerous cells. While HDM-2 predominantly functions as a nuclear and cytoplasmic E3 ubiquitin ligase in untransformed cells, malignant transformation often results in aberrant localization of HDM-2 to the plasma membrane.

In vitro data indicate that PNC-27 selectively docks with this membrane-bound HDM-2 receptor complex. The structural complementarity between the p53 residues (12–26) in PNC-27 and the hydrophobic binding pocket of HDM-2 facilitates a high-affinity association. Because this extracellular interaction does not require internalization or nuclear translocation to initiate its physical effect, investigators utilize PNC-27 to probe cell surface protein topology and membrane destabilization mechanisms.

p53-Independent Pore Formation and Necrotic Cascade

A defining operational feature of PNC-27 in cell biology assays is its p53-independent mode of action. Classical oncological therapies and peptide constructs often rely on reinstating p53-mediated transcriptional activation to trigger programmed cell death (apoptosis). In contrast, in vitro research demonstrates that PNC-27 induces cell death in p53-homozygous null, p53-mutated, and p53-wild-type cancer cell lines with equivalent potency.

Upon binding cell-surface HDM-2, the transmembrane-penetrating domain of PNC-27 undergoes an amphipathic structural transition that inserts into the lipid bilayer. This step leads to oligomerization and the rapidly formed transmembrane pores. The resultant loss of membrane integrity triggers an uncontrolled influx of extracellular ions, rapid loss of ATP, cell swelling, and immediate necrosis. Because the mechanism relies entirely on physical pore formation rather than metabolic cascades, researchers frequently use PNC-27 as a positive control for rapid membrane lysis in cytotoxicity assays.

PNC-27 2mg Reconstitution Mathematics and Calculations

Accurate reconstitution is essential for establishing uniform concentration profiles in microplate assays. When working with a 2mg (2,000 µg) vial of lyophilized PNC-27, the concentration of the stock solution depends directly on the volume of sterile diluent added (such as laboratory-grade sterile water or phosphate-buffered saline).

To achieve target working concentrations, researchers should apply the following volumetric calculations: - Addition of 1.0 mL diluent yields a final concentration of 2.0 mg/mL (2.0 µg/µL). - Addition of 2.0 mL diluent yields a final concentration of 1.0 mg/mL (1.0 µg/µL). - Addition of 3.0 mL diluent yields a final concentration of 0.67 mg/mL (0.67 µg/µL).

For precise micro-volume pipetting and custom assay dilutions, scientists can calculate exact liquid handling parameters using the PX1 /reconstitution-calculator. Ensuring that stock solutions are properly calculated prevents compound waste and maintains assay reproducibility across multi-well assays.

Aliquoting Protocols, Solubilization, and Storage

Lyophilized PNC-27 should be stored at -20°C or -80°C in a dry environment protected from light prior to reconstitution. When preparing the vial for liquid assay handling, allow the container to reach room temperature before removing the stopper to prevent atmospheric condensation from contaminating the cake. Reconstitution should be performed by gently running the diluent down the glass vial wall, followed by mild swirl agitation; vortexing should be strictly avoided to prevent mechanical shearing or peptide aggregation.

Once reconstituted, single-use aliquoting is strongly recommended. Freezing and thawing reconstituted peptide solutions induces ice crystal formation that degrades peptide secondary structure and lowers active recovery. Stock aliquots stored at -80°C retain physical stability for extended periods, whereas working aliquots maintained at 4°C should be utilized within 24 to 48 hours to preserve experimental fidelity.

Comparative Structural Class: PNC-27 vs. PNC-28 and HDM-2 Inhibitors

In comparative oncological research, PNC-27 is frequently evaluated alongside structural analogs and traditional small-molecule antagonists. For instance, PNC-28 is a closely related peptide construct comprising p53 residues 17–26 linked to the same cell-penetrating leader sequence. While both exhibit pore-forming necrotic activity against membrane-bound HDM-2 expressing cells, subtle structural differences in their binding regions yield distinct alpha-helical stability and binding kinetics in different cell line models.

Conversely, traditional HDM-2 inhibitors and p53-reactivating small molecules function primarily by disrupting the intracellular HDM-2/p53 complex within the nucleoplasm. This action releases wild-type p53 to activate apoptotic gene transcription. In contrast, membrane-active agents like PNC-27 bypass nuclear entry entirely, offering a distinct mechanism for targeting p53-resistant lines. Researchers studying broader cell lysis models may also compare these with general cell-lysis peptides to delineate target-specific pore formation from non-specific detergent effects.

Analytical Certificate of Analysis (COA) Standards

Every batch of PNC-27 produced for PX1 Research undergoes strict analytical evaluation to ensure purity and identity verification prior to release. Laboratory researchers rely on lot-matched documentation to confirm that experimental variables remain strictly controlled. The lot-specific Certificate of Analysis outlines critical analytical metrics including high-performance liquid chromatography (HPLC) chromatograms and mass spectrometry (MS) spectra.

To verify analytical parameters for any specific batch, investigators can access the dedicated /coa repository. For PNC-27 2mg, standard quality parameters mandate greater than 98% purity as measured by RP-HPLC, with electrospray ionization mass spectrometry (ESI-MS) confirming the expected molecular weight without secondary adducts or truncated synthesis fragments.

USA Manufacturing, ISO 17025 Integrity, and Endotoxin Control

Biological assays involving cell cultures are exceptionally sensitive to bacterial endotoxins and chemical contaminants. Lipopolysaccharides (LPS) present in poorly purified peptide batches can induce non-specific toll-like receptor (TLR) activation, masking true necrotic outcomes or introducing severe confounding variables. PX1 Research mandates that all PNC-27 2mg lots are manufactured in USA-based, GMP-compliant facilities and tested in ISO 17025 accredited analytical laboratories.

Endotoxin levels are verified using quantitative Limulus Amebocyte Lysate (LAL) testing, establishing limits below 0.05 EU/mg. This process ensures that cell lysis observed in vitro is directly attributable to the pore-forming mechanics of PNC-27 rather than endotoxin-mediated cytotoxicity. Institutional facilities requiring large-scale batch uniformity or custom supply agreements can coordinate bulk logistics through the /wholesale portal.

Selecting Between 2mg and 5mg Configurations

Choosing the optimal vial mass depends entirely on the design and scale of the planned experimental matrix. A 2mg vial of PNC-27 is ideally suited for initial dose-response curve generation, assay optimization, or pilot cell viability screens where minimizing liquid stock storage time is critical. Using a smaller mass unit ensures that the peptide is consumed across a limited number of plate runs, avoiding prolonged freezer storage of reconstituted stock.

Conversely, high-throughput screening initiatives or extensive comparative panel studies utilizing dozens of cell lines may benefit from larger unit masses (such as 5mg vials) to maintain single-lot consistency across expanded assay timelines. If PX1 Research lists custom batch configurations or alternative mass offerings, researchers should evaluate total volumetric consumption during protocol design. Detailed documentation on peptide mechanics and experimental literature is maintained within the PX1 /research library.